Charles Newhall, Director at Supernus Pharmaceuticals, holds 97.51K shares in Supernus Pharmaceuticals (Ticker: SUPN), holds 289.00 shares in Vitae Pharma (Ticker: VTAE), holds 2.88M shares in Hyperion Therapeutics (Ticker: HPTX).
Charles Newhall latest transaction was an Uninformative Buy of $125.01K.
What was Charles Newhall's most profitable transaction?
Charles Newhall’s most profitable transaction was an Informative Buy of GRPN stock on November 3, 2011. The return on the trade was 283.00%.
What is Charles Newhall's role in Supernus Pharmaceuticals?
Charles Newhall's role in Supernus Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.